Efbemalenograstim alfa
Medication / From Wikipedia, the free encyclopedia
Efbemalenograstim alfa, sold under the brand name Ryzneuta, is a medication used to decrease the incidence of infection in chemotherapy-induced neutropenia.[1] It is a leukocyte growth factor.[1] It is given by subcutaneous injection.[1]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | Ryzneuta |
Other names | F-627, efbemalenograstim alfa-vuxw, benegrastim |
AHFS/Drugs.com | Monograph |
MedlinePlus | a624001 |
License data | |
Routes of administration | Subcutaneous |
Drug class | Immunological agent |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
UNII | |
KEGG |
Close
Efbemalenograstim alfa is an immunostimulant/colony stimulating factor that belongs to the class of hematopoietic growth factors (granulocyte colony stimulating factor; G CSF) which increase the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells.[2]
It was approved for medical use in China in May 2023,[4] in the United States in November 2023,[1][5] and in the European Union in March 2024.[2][3]